Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Prostate Cancer
79%
Chemotherapy
49%
Malignant Neoplasm
48%
Overall Survival
41%
Androgen Receptor
36%
Docetaxel
34%
Disease
31%
Clinical Trial
29%
Cisplatin
26%
Androgen
20%
Renal Cell Carcinoma
19%
Transitional Cell Carcinoma
19%
Kidney Metastasis
17%
Kidney Cancer
17%
Solid Malignant Neoplasm
16%
Biological Marker
16%
Prostate Specific Antigen
16%
Cabazitaxel
15%
Adverse Event
13%
Bladder Cancer
12%
Prevalence
12%
Metastasis
12%
Diseases
11%
Progression Free Survival
11%
Phase II Trials
10%
Adrenergic Receptor
10%
Gemcitabine
10%
Statin (Protein)
10%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Taxane
9%
Comorbidity
8%
Prednisone
8%
Neoplasm
8%
Thromboembolism
8%
Febrile Neutropenia
8%
Urogenital Tract Cancer
7%
Randomized Controlled Trial
6%
Satraplatin
6%
Disease Exacerbation
6%
Cytotoxic Chemotherapy
6%
Immunotherapy
6%
Vasculotropin
6%
Observational Study
6%
Abiraterone Acetate
6%
Neutropenia
6%
Repurposing
5%
Chronic Kidney Failure
5%
Atezolizumab
5%
Coronavirinae
5%
Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
86%
Prostate Cancer
48%
Castration-resistant Prostate Cancer
35%
Renal Cell Carcinoma
34%
Overall Survival
34%
Androgen Receptor Targeted Therapy
31%
Docetaxel
30%
Metastatic Renal Cell Carcinoma (mRCC)
23%
Clinical Trials
21%
Patients with Prostate Cancer
21%
Renal Cancer
20%
Phase II Trial
19%
Cisplatin
19%
United States
19%
Chemotherapy
17%
Solid Tumors
16%
Cabazitaxel
15%
Immune Checkpoint Inhibitors
15%
Risk Factors
15%
Performance Status
14%
Cisplatin-based Chemotherapy
14%
Bladder Cancer
13%
Metastatic Disease
13%
Clinical Development
13%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
13%
Renal Mass
13%
Tumor Characteristics
13%
Cystectomy
12%
Androgen Deprivation Therapy
12%
Odds Ratio
12%
Clear Cell Renal Cell Carcinoma (ccRCC)
12%
Confidence Interval
12%
Progression-free Survival
12%
Advanced Solid Tumors
11%
Advanced Prostate Cancer
11%
Survival Outcomes
11%
Clinical Outcomes
11%
Black Men
11%
Meta-analysis
11%
Metastatic Urothelial Carcinoma
10%
Muscle-invasive Bladder Cancer
10%
Systematic Meta-analysis
10%
Targeted Therapy
10%
Cytoreductive Nephrectomy
10%
Vascular Endothelial Growth Factor
10%
Gemcitabine Plus Cisplatin
10%
End-of-life Outcomes
10%
Clinical Management
10%
Statins
10%
Statin Use
10%
Medicine and Dentistry
Prostate Cancer
56%
Castration Resistant Prostate Cancer
44%
Clear Cell Renal Cell Carcinoma
33%
Disease
25%
Metastatic Carcinoma
24%
Targeted Therapy
20%
Malignant Neoplasm
20%
Overall Survival
20%
Transitional Cell Carcinoma
19%
Bladder Cancer
19%
Chemotherapy
18%
Solid Malignant Neoplasm
18%
Clinical Trial
17%
Neoplasm
17%
Immune Checkpoint Inhibitor
17%
Kidney Cancer
17%
Cystectomy
15%
Kidney Tumour
12%
Biological Marker
12%
Vasculotropin
12%
Kidney Metastasis
11%
Androgen Receptor
11%
Prostate Specific Antigen
10%
Muscle Invasive Bladder Cancer
10%
Circulating Tumor DNA
10%
Systemic Therapy
9%
Diseases
8%
Oncology
8%
Cisplatin
7%
Cancer
7%
Cancer Types
7%
Urothelial Cancer
7%
Prevalence
7%
Urogenital Tract Cancer
7%
Satraplatin
6%
Immune Response
6%
Inferior Vena Cava
6%
Adjuvant Chemotherapy
6%
Shared Decision Making
6%
Lymph Node
6%
Adverse Event
6%
Observational Study
6%
Neoadjuvant Chemotherapy
6%
Cancer Cell
5%
Chronic Kidney Disease
5%
DNA Repair
5%
Cancer Diagnosis
5%
Biopsy Technique
5%
Kidney Function
5%
Docetaxel
5%